Ireland asthma
treatment market is expected to grow at steady rate an impressive rate
during the forecast period on account of rising prevalence of asthma,
increase in air pollution, rise in number of product launches, increase in
number of clinical trials for better clinical and therapeutics for asthma is
expected to drive the growth of Ireland asthma treatment market during the
forecast period. For instance, according to Center for Disease Control
and Prevention (CDC), during the coronavirus pandemic, individuals suffering
from moderate to severe asthma were at a greater risk of falling ill with acute
respiratory disease. Furthermore, rising healthcare expenditure and
rise in research and development is expected to bolster the growth of the
Ireland asthma treatment market. These factors are actively driving the growth
of the Ireland asthma treatment market in the upcoming five years, 2024-2028.
Asthma is a chronic
respiratory condition characterized by inflammation and narrowing of the
airways, which results in recurring episodes of wheezing, coughing, shortness
of breath, and chest tightness. It is a common condition that affects the lungs
and can vary in severity from mild to severe. For some people, it became a
major concern and causes difficulty in their daily activities and could result
in life threatening asthma attack, which is also known as asthma exacerbation.
When a person with asthma is exposed to certain triggers, such as allergens
(dust mites, pollen, pet dander), respiratory infections, irritants (smoke,
strong odors, air pollution), exercise, or changes in weather, the airways become
inflamed. This inflammation causes the muscles surrounding the airways to
tighten and the lining of the airways to produce excess mucus, leading to the
characteristic symptoms of asthma.
One of the key
drivers of growth in the Ireland asthma treatment market is rise in geriatric
population. According to National Institute of Health, the prevalence
of the four main categories of chronic diseases among adults in Ireland has
been estimated to be 9.4% for asthma, 9.8% for Chronic obstructive pulmonary
disease (COPD), 5.2% for diabetes, and 4.3% for Cardiovascular (CVD).
Another factor driving growth in the Ireland asthma treatment market is the
rising interest of different market players for new product launches. According
to the National Institute of Health, approximately 470,000 people have asthma
in Ireland and 6,300 people have severe asthma. The European Community
Respiratory Health Survey (ECRHS) reported that Ireland has the highest
prevalence of severe asthma attacks (6%) over the past 12 months among patients
aged 20–44 years across Europe. Infact, the government has made healthcare
a priority and has allocated significant resources to improve healthcare
investment and services. This has created a favorable environment for market
players, with a growing demand for developing new products and services.
Additionally, the
manufacturers in the asthma treatment market are introducing new therapies and
products that reduces the prevalence of life-threatening or uncontrolled asthma
attack in patients. Asthma is one of the most common non-communicable diseases
in children, and its prevalence varies across countries. For instance,
International Study of Asthma and Allergies in Childhood (ISAAC), using a
simple and inexpensive standardized methodology, has provided valuable data on
the prevalence of the symptoms of childhood asthma and allergies for
international comparison from countries with different socio-economic
backgrounds.
Furthermore, the
ongoing research and development of technology in the development of therapy
for asthma treatment is expected to aid the growth of the Ireland asthma
treatment market in the forecast period, 2024-2028. Moreover, the government
also supports the idea by increasing investment in the pharmaceutical sector
and the pharmaceutical companies to enforce manufacturers for taking interest
in research and development of advanced therapies in Ireland to bolster the
growth of Ireland asthma treatment market.
Rising Prevalence of Chronic Diseases
Asthma is the most common chronic disease. For
instance, according to WHO, asthma affected about 262 million people and
455,000 people succumbed to the disease in 2019. Majority of asthma related
deaths occur in low and lower middle-income countries where underdiagnosis and
undertreatment are common. Asthma can be a persisting and recurring health
problem, thus increasing the likelihood of health, social, and economic costs
for the individuals, their families and on the healthcare system across the
country. We can prevent from asthma by proceeding with reduced tobacco,
affordable medication, long term illness scheme, DPS threshold reduction, clean
outdoor air, clear outdoor air in the home. According to Asthma society
of Ireland, in 2019, 890,000 people experience asthma at some stage of their
life in which 380,000 people in Ireland currently have asthma.
Additionally, the increasing number of diagnosed cases and
awareness of asthma contribute to the demand for effective treatment options. In Ireland, it is estimated that up to 60% of
people with asthma don’t have their condition under control. For many people,
this is due to the high cost of the essential controller medication which forms
the core of asthma management. Controller inhalers can cost up to €70 each per
month and asthma, despite being a lifelong condition, is not included in the
long-term illness scheme in Ireland. As a result, these people are at risk of
an asthma attack and the development of new therapies will lead to the propel
the growth of Ireland asthma treatment market.
Furthermore, a higher prevalence of asthma in the
population directly translates to an increased demand for asthma treatment. As
more individuals are diagnosed with asthma, the need for effective treatment
options rises. This creates a larger market for pharmaceutical companies and
healthcare providers to cater to. With a higher prevalence of asthma, there is
an increased focus on improving treatment accessibility. Healthcare providers
and professionals are more likely to prioritize asthma management programs,
ensuring that patients have access to appropriate medications, healthcare
services, and education. This accessibility drives the growth of Ireland asthma
treatment market.
Increasing Air Pollution Triggering Asthma Cases
Asthma is a chronic respiratory condition marked by
fluctuating airflow restriction, bronchial hyper responsiveness, and
inflammation of the airways. Air pollution appears to have a negative impact on
asthma outcomes in both adults and children. For instance, according to
research, the air pollution from traffic, nitrogen dioxide, and second-hand
smoking (SHS) are all substantial risk factors for the development of asthma in
children. Asthma symptoms, exacerbations, and decreased lung function can
all be triggered by exposure to outside pollution as the outside environment is
very polluted and is expected to bolster the growth of Ireland asthma treatment
market.
Download Free Sample Report
Recent Developments
In March 2023, a
company namely Astra Zeneca Pharmaceuticals Ltd, Amgen’s Asthma had launched
Tezspire picks up backing from England’s Nice. Tezspire won approvals in the
U.K. and Europe in September 2022. The asthma biologic won an FDA endorsement
in late 2021. TEZSPIRE proactively helps reduce inflammation in patients
with severe asthma which provides better breathing with improved lung function.
In April 2020, EMA’s
human medicines committee (CHMP) has recommended granting a marketing
authorization in the European Union for Enerzair breezhaler, a new asthma
treatment which includes an optional digital sensor. This is the first asthma
triple combination therapy; it consists of a fixed dose combination of three
active substances (indacaterol, glycopyrronium and mometasone furoate) in
capsules, to be administered using an inhaler. An optional electronic sensor
may also be co-packed with the product. The sensor will be attached to the base
of the inhaler to collect data on the use of the inhaler by the patient. The
sensor will send the data to an app on a smart phone or other suitable device.
In July 2020,
Novartis AG today announced that the European Commission (EC) has approved
Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and
mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult
patients not adequately controlled with a maintenance combination of a long‑acting
beta2‑agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who
experienced one or more asthma exacerbations in the previous year. Once-daily
Enerzair Breezhaler is the first LABA/long-acting muscarinic antagonist
(LAMA)/ICS fixed-dose combination available in the EU for asthma patients.
Market Segmentation
The Ireland asthma
treatment market is segmented by treatment, route of administration,
distribution channel, regional distribution, and competitional landscape. Based
on treatment, the market is further bifurcated into long term medications
and quick relief medications. Based on route of administration, the market is
bifurcated into injectable, oral, and inhaled. Based on distribution channel,
the market is bifurcated into hospital pharmacies, retail pharmacies &
drug stores, and online pharmacies.
Market Players
AstraZeneca
Pharmaceuticals Ireland, Fresenius Kabi Ireland, GlaxoSmithKline Ireland, Teva
Pharmaceuticals Ireland Limited, Novartis Ireland Limited, Sanofi Aventis
Ireland Ltd, Hoffmann-La Roche Ireland Limited, Regeneron Ireland, and Merck
& Co. Ireland Limited are some of the leading companies operating in
the Ireland asthma treatment market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historical
Years
|
2018 –
2022
|
|
Estimated
Year
|
2022E
|
|
Forecast
Period
|
2023F
– 2028F
|
|
Quantitative
Units
|
Revenue
in USD Million, Volume in Units, and CAGR for 2017-2021 and 2022E-2028F
|
|
Report
Coverage
|
Revenue
forecast, volume forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments
Covered
|
Treatment
Route
of Administration
Distribution
Channel
Region
Company
|
|
Region
Scope
|
Northern
Ireland, North-West, West, Midland East, Dublin, Shannon, South-East,
Cork-Kerry
|
|
Key
Companies Profiled
|
AstraZeneca
Pharmaceuticals Ireland, Fresenius Kabi Ireland, GlaxoSmithKline Ireland,
Teva Pharmaceuticals Ireland Limited, Novartis Ireland Limited, Sanofi
Aventis Ireland Ltd, Hoffmann-La Roche Ireland Limited, Regeneron Ireland,
Merck & Co. Ireland Limited
|
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to regional
& segment scope.
|
|
Pricing
and Purchase Options
|
Avail
customized purchase options to meet your exact research needs. Explore
purchase options
|
|
Delivery
Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report Scope:
In this report, Ireland asthma
treatment market has been segmented into following categories, in addition
to the industry trends which have also been detailed below:
- Ireland
Asthma Treatment Market, By Treatment:
o
Long Term Medications
o
Quick Relief Medications
- Ireland
Asthma Treatment Market, By Route of Administration:
o
Injectable
o
Oral
o
Inhaled
- Ireland Asthma Treatment
Market, By Distribution Channel:
o
Hospital Pharmacies
o
Retail Pharmacies & Drug Stores
o
Online Pharmacies
- Ireland
Asthma Treatment Market, By Region:
o
Northern Ireland
o
North-West
o
West
o
Midland East
o
Dublin
o
Shannon
o
South-East
o
Cork-Kerry
Competitive Landscape
Company Profiles: Detailed analysis of the major
companies present in Ireland asthma treatment market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
It is an upcoming report to be
released soon. If you wish and early delivery of this report or want to confirm
the date of release, please contact us at [email protected]